Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 716

1.

Longitudinal Assessment of Left Ventricular Mass in Autosomal Dominant Polycystic Kidney Disease.

Dad T, Abebe KZ, Bae KT, Comer D, Torres VE, Czarnecki PG, Schrier RW, Steinman TI, Moore CG, Chapman AB, Kaya D, Tao C, Braun WE, Winklhofer FT, Brosnahan G, Hogan MC, Miskulin DC, Rahbari Oskoui F, Flessner MF, Perrone RD.

Kidney Int Rep. 2018 Jan 6;3(3):619-624. doi: 10.1016/j.ekir.2017.12.011. eCollection 2018 May.

2.

Patterns of Kidney Function Decline in Autosomal Dominant Polycystic Kidney Disease: A Post Hoc Analysis From the HALT-PKD Trials.

Brosnahan GM, Abebe KZ, Moore CG, Rahbari-Oskoui FF, Bae KT, Grantham JJ, Schrier RW, Braun WE, Chapman AB, Flessner MF, Harris PC, Hogan MC, Perrone RD, Miskulin DC, Steinman TI, Torres VE; HALT-PKD Trial Investigators.

Am J Kidney Dis. 2018 May;71(5):666-676. doi: 10.1053/j.ajkd.2017.10.023. Epub 2018 Jan 3.

3.

ADPKD Progression in Patients With No Apparent Family History and No Mutation Detected by Sanger Sequencing.

Braun WE, Abebe KZ, Brosnahan G, Patterson CG, Chapman AB, Harris PC, Hogan MC, Perrone RD, Torres VE, Miskulin DC, Steinman TI, Winklhofer FT, Rahbari-Oskoui FF, Czarnecki PG, Bae KT, Grantham JJ, Flessner MF, Schrier RW.

Am J Kidney Dis. 2018 Feb;71(2):294-296. doi: 10.1053/j.ajkd.2017.09.008. Epub 2017 Dec 2. No abstract available.

4.

Fibroblast Growth Factor 23 and Kidney Disease Progression in Autosomal Dominant Polycystic Kidney Disease.

Chonchol M, Gitomer B, Isakova T, Cai X, Salusky I, Pereira R, Abebe K, Torres V, Steinman TI, Grantham JJ, Chapman AB, Schrier RW, Wolf M.

Clin J Am Soc Nephrol. 2017 Sep 7;12(9):1461-1469. doi: 10.2215/CJN.12821216. Epub 2017 Jul 13.

5.

Effect of Statin Therapy on the Progression of Autosomal Dominant Polycystic Kidney Disease. A Secondary Analysis of the HALT PKD Trials.

Brosnahan GM, Abebe KZ, Rahbari-Oskoui FF, Patterson CG, Bae KT, Schrier RW, Braun WE, Chapman AB, Flessner MF, Harris PC, Perrone RD, Steinman TI, Torres VE; HALT PKD Investigators.

Curr Hypertens Rev. 2017;13(2):109-120. doi: 10.2174/1573402113666170427142815.

6.

Dietary salt restriction is beneficial to the management of autosomal dominant polycystic kidney disease.

Torres VE, Abebe KZ, Schrier RW, Perrone RD, Chapman AB, Yu AS, Braun WE, Steinman TI, Brosnahan G, Hogan MC, Rahbari FF, Grantham JJ, Bae KT, Moore CG, Flessner MF.

Kidney Int. 2017 Feb;91(2):493-500. doi: 10.1016/j.kint.2016.10.018. Epub 2016 Dec 16.

7.

ACE inhibitors, left ventricular mass and renal cyst growth in ADPKD.

Schrier RW.

Pharmacol Res. 2016 Dec;114:166-168. doi: 10.1016/j.phrs.2016.10.002. Epub 2016 Oct 26. Review.

PMID:
27794499
8.

Long-Term Outcomes in Patients with Very-Early Onset Autosomal Dominant Polycystic Kidney Disease.

Nowak KL, Cadnapaphornchai MA, Chonchol MB, Schrier RW, Gitomer B.

Am J Nephrol. 2016;44(3):171-8. doi: 10.1159/000448695. Epub 2016 Aug 23.

9.

Prognostic enrichment design in clinical trials for autosomal dominant polycystic kidney disease: the HALT-PKD clinical trial.

Irazabal MV, Abebe KZ, Bae KT, Perrone RD, Chapman AB, Schrier RW, Yu AS, Braun WE, Steinman TI, Harris PC, Flessner MF, Torres VE; HALT Investigators.

Nephrol Dial Transplant. 2017 Nov 1;32(11):1857-1865. doi: 10.1093/ndt/gfw294.

10.

Predicted Mutation Strength of Nontruncating PKD1 Mutations Aids Genotype-Phenotype Correlations in Autosomal Dominant Polycystic Kidney Disease.

Heyer CM, Sundsbak JL, Abebe KZ, Chapman AB, Torres VE, Grantham JJ, Bae KT, Schrier RW, Perrone RD, Braun WE, Steinman TI, Mrug M, Yu AS, Brosnahan G, Hopp K, Irazabal MV, Bennett WM, Flessner MF, Moore CG, Landsittel D, Harris PC; HALT PKD and CRISP Investigators.

J Am Soc Nephrol. 2016 Sep;27(9):2872-84. doi: 10.1681/ASN.2015050583. Epub 2016 Jan 28.

11.

Decade in review--polycystic kidney disease: Slowing progression of autosomal dominant polycystic kidney disease.

Schrier RW.

Nat Rev Nephrol. 2015 Nov;11(11):638-9. doi: 10.1038/nrneph.2015.164. Epub 2015 Oct 13. No abstract available.

PMID:
26460355
12.

Clinical Use of Diuretics in Heart Failure, Cirrhosis, and Nephrotic Syndrome.

Qavi AH, Kamal R, Schrier RW.

Int J Nephrol. 2015;2015:975934. doi: 10.1155/2015/975934. Epub 2015 Jul 29. Review.

13.

Closeout of the HALT-PKD trials.

Moore CG, Spillane S, Simon G, Maxwell B, Rahbari-Oskoui FF, Braun WE, Chapman AB, Schrier RW, Torres VE, Perrone RD, Steinman TI, Brosnahan G, Czarnecki PG, Harris PC, Miskulin DC, Flessner MF, Bae KT, Abebe KZ, Hogan MC.

Contemp Clin Trials. 2015 Sep;44:48-55. doi: 10.1016/j.cct.2015.07.017. Epub 2015 Jul 29.

14.

Pravastatin Therapy and Biomarker Changes in Children and Young Adults with Autosomal Dominant Polycystic Kidney Disease.

Klawitter J, McFann K, Pennington AT, Wang W, Klawitter J, Christians U, Schrier RW, Gitomer B, Cadnapaphornchai MA.

Clin J Am Soc Nephrol. 2015 Sep 4;10(9):1534-41. doi: 10.2215/CJN.11331114. Epub 2015 Jul 29.

15.

Therapeutic Area Data Standards for Autosomal Dominant Polycystic Kidney Disease: A Report From the Polycystic Kidney Disease Outcomes Consortium (PKDOC).

Perrone RD, Neville J, Chapman AB, Gitomer BY, Miskulin DC, Torres VE, Czerwiec FS, Dennis E, Kisler B, Kopko S, Krasa HB, LeRoy E, Castedo J, Schrier RW, Broadbent S.

Am J Kidney Dis. 2015 Oct;66(4):583-90. doi: 10.1053/j.ajkd.2015.04.044. Epub 2015 Jun 15. Review.

PMID:
26088508
16.

Autosomal-dominant polycystic kidney disease (ADPKD): executive summary from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference.

Chapman AB, Devuyst O, Eckardt KU, Gansevoort RT, Harris T, Horie S, Kasiske BL, Odland D, Pei Y, Perrone RD, Pirson Y, Schrier RW, Torra R, Torres VE, Watnick T, Wheeler DC; Conference Participants.

Kidney Int. 2015 Jul;88(1):17-27. doi: 10.1038/ki.2015.59. Epub 2015 Mar 18.

17.

Blood pressure in early autosomal dominant polycystic kidney disease.

Schrier RW.

N Engl J Med. 2015 Mar 5;372(10):976-7. doi: 10.1056/NEJMc1500332. No abstract available.

PMID:
25738676
18.

Mineralocorticoid receptor antagonists as diuretics: Can congestive heart failure learn from liver failure?

Masoumi A, Ortiz F, Radhakrishnan J, Schrier RW, Colombo PC.

Heart Fail Rev. 2015 May;20(3):283-90. doi: 10.1007/s10741-014-9467-2. Review.

19.

Blood pressure in early autosomal dominant polycystic kidney disease.

Schrier RW, Abebe KZ, Perrone RD, Torres VE, Braun WE, Steinman TI, Winklhofer FT, Brosnahan G, Czarnecki PG, Hogan MC, Miskulin DC, Rahbari-Oskoui FF, Grantham JJ, Harris PC, Flessner MF, Bae KT, Moore CG, Chapman AB; HALT-PKD Trial Investigators.

N Engl J Med. 2014 Dec 11;371(24):2255-66. doi: 10.1056/NEJMoa1402685. Epub 2014 Nov 15.

20.

Angiotensin blockade in late autosomal dominant polycystic kidney disease.

Torres VE, Abebe KZ, Chapman AB, Schrier RW, Braun WE, Steinman TI, Winklhofer FT, Brosnahan G, Czarnecki PG, Hogan MC, Miskulin DC, Rahbari-Oskoui FF, Grantham JJ, Harris PC, Flessner MF, Moore CG, Perrone RD; HALT-PKD Trial Investigators.

N Engl J Med. 2014 Dec 11;371(24):2267-76. doi: 10.1056/NEJMoa1402686. Epub 2014 Nov 15.

21.

Endothelial dysfunction and oxidative stress in polycystic kidney disease.

Klawitter J, Reed-Gitomer BY, McFann K, Pennington A, Klawitter J, Abebe KZ, Klepacki J, Cadnapaphornchai MA, Brosnahan G, Chonchol M, Christians U, Schrier RW.

Am J Physiol Renal Physiol. 2014 Dec 1;307(11):F1198-206. doi: 10.1152/ajprenal.00327.2014. Epub 2014 Sep 18.

22.

Liver involvement in early autosomal-dominant polycystic kidney disease.

Hogan MC, Abebe K, Torres VE, Chapman AB, Bae KT, Tao C, Sun H, Perrone RD, Steinman TI, Braun W, Winklhofer FT, Miskulin DC, Rahbari-Oskoui F, Brosnahan G, Masoumi A, Karpov IO, Spillane S, Flessner M, Moore CG, Schrier RW.

Clin Gastroenterol Hepatol. 2015 Jan;13(1):155-64.e6. doi: 10.1016/j.cgh.2014.07.051. Epub 2014 Aug 9.

23.

The reply.

Verbalis JG, Goldsmith SR, Greenberg A, Korzelius C, Schrier RW, Sterns RH, Thompson CJ.

Am J Med. 2014 Jul;127(7):e31-2. doi: 10.1016/j.amjmed.2014.03.022. No abstract available.

PMID:
24970609
24.

Predictors of autosomal dominant polycystic kidney disease progression.

Schrier RW, Brosnahan G, Cadnapaphornchai MA, Chonchol M, Friend K, Gitomer B, Rossetti S.

J Am Soc Nephrol. 2014 Nov;25(11):2399-418. doi: 10.1681/ASN.2013111184. Epub 2014 Jun 12. Review.

25.

Hormones and hemodynamics in pregnancy.

Tkachenko O, Shchekochikhin D, Schrier RW.

Int J Endocrinol Metab. 2014 Apr 1;12(2):e14098. doi: 10.5812/ijem.14098. eCollection 2014 Apr. Review.

26.

Effect of pravastatin on total kidney volume, left ventricular mass index, and microalbuminuria in pediatric autosomal dominant polycystic kidney disease.

Cadnapaphornchai MA, George DM, McFann K, Wang W, Gitomer B, Strain JD, Schrier RW.

Clin J Am Soc Nephrol. 2014 May;9(5):889-96. doi: 10.2215/CJN.08350813. Epub 2014 Apr 10.

27.

Bioactive lipid mediators in polycystic kidney disease.

Klawitter J, Klawitter J, McFann K, Pennington AT, Abebe KZ, Brosnahan G, Cadnapaphornchai MA, Chonchol M, Gitomer B, Christians U, Schrier RW.

J Lipid Res. 2014 Jun;55(6):1139-49. doi: 10.1194/jlr.P042176. Epub 2013 Dec 16.

28.

Health-related quality of life in patients with autosomal dominant polycystic kidney disease and CKD stages 1-4: a cross-sectional study.

Miskulin DC, Abebe KZ, Chapman AB, Perrone RD, Steinman TI, Torres VE, Bae KT, Braun W, Winklhofer FT, Hogan MC, Rahbari-Oskoui F, Moore CG, Flessner MF, Schrier RW; HALT-PKD Study.

Am J Kidney Dis. 2014 Feb;63(2):214-26. doi: 10.1053/j.ajkd.2013.08.017. Epub 2013 Nov 1.

29.

Diagnosis, evaluation, and treatment of hyponatremia: expert panel recommendations.

Verbalis JG, Goldsmith SR, Greenberg A, Korzelius C, Schrier RW, Sterns RH, Thompson CJ.

Am J Med. 2013 Oct;126(10 Suppl 1):S1-42. doi: 10.1016/j.amjmed.2013.07.006.

PMID:
24074529
30.

The nephrotic syndrome: pathogenesis and treatment of edema formation and secondary complications.

Cadnapaphornchai MA, Tkachenko O, Shchekochikhin D, Schrier RW.

Pediatr Nephrol. 2014 Jul;29(7):1159-67. doi: 10.1007/s00467-013-2567-8. Epub 2013 Aug 30. Review.

PMID:
23989393
31.

Renin-Angiotensin-aldosterone system in autosomal dominant polycystic kidney disease.

Tkachenko O, Helal I, Shchekochikhin D, Schrier RW.

Curr Hypertens Rev. 2013 Feb;9(1):12-20. Review.

PMID:
23971639
32.

Effects of lovastatin treatment on the metabolic distributions in the Han:SPRD rat model of polycystic kidney disease.

Klawitter J, Zafar I, Klawitter J, Pennington AT, Klepacki J, Gitomer BY, Schrier RW, Christians U, Edelstein CL.

BMC Nephrol. 2013 Jul 31;14:165. doi: 10.1186/1471-2369-14-165.

33.

Changing referral characteristics of patients with autosomal dominant polycystic kidney disease.

Helal I, McFann K, Reed B, Yan XD, Schrier RW.

Am J Med. 2013 Sep;126(9):832.e7-832.e11. doi: 10.1016/j.amjmed.2012.12.018. Epub 2013 Jul 3.

PMID:
23830538
34.

Kidney failure: aims for the next 10 years and barriers to success.

Remuzzi G, Benigni A, Finkelstein FO, Grunfeld JP, Joly D, Katz I, Liu ZH, Miyata T, Perico N, Rodriguez-Iturbe B, Antiga L, Schaefer F, Schieppati A, Schrier RW, Tonelli M.

Lancet. 2013 Jul 27;382(9889):353-62. doi: 10.1016/S0140-6736(13)60438-9. Epub 2013 May 31. Review.

PMID:
23727164
35.

Cardiorenal syndrome: pathophysiology and treatment.

Shchekochikhin D, Schrier RW, Lindenfeld J.

Curr Cardiol Rep. 2013 Jul;15(7):380. doi: 10.1007/s11886-013-0380-4. Review.

PMID:
23700289
36.

Outcome differences in community- versus hospital-acquired hyponatremia in patients with a diagnosis of heart failure.

Shchekochikhin DY, Schrier RW, Lindenfeld J, Price LL, Jaber BL, Madias NE.

Circ Heart Fail. 2013 May;6(3):379-86. doi: 10.1161/CIRCHEARTFAILURE.112.000106. Epub 2013 Mar 19.

PMID:
23512983
37.

Hyponatremia: an update on current pharmacotherapy.

Shchekochikhin D, Tkachenko O, Schrier RW.

Expert Opin Pharmacother. 2013 Apr;14(6):747-55. doi: 10.1517/14656566.2013.781584. Review.

PMID:
23496346
38.

Serum uric acid, kidney volume and progression in autosomal-dominant polycystic kidney disease.

Helal I, McFann K, Reed B, Yan XD, Schrier RW, Fick-Brosnahan GM.

Nephrol Dial Transplant. 2013 Feb;28(2):380-5. doi: 10.1093/ndt/gfs417. Epub 2012 Dec 4.

39.

Hyponatraemia: more than just a marker of disease severity?

Schrier RW, Sharma S, Shchekochikhin D.

Nat Rev Nephrol. 2013 Jan;9(1):37-50. doi: 10.1038/nrneph.2012.246. Epub 2012 Nov 20. Review. Erratum in: Nat Rev Nephrol. 2013 Mar;9(3):124.

PMID:
23165296
40.

Prevalence of cardiovascular events in patients with autosomal dominant polycystic kidney disease.

Helal I, Reed B, Mettler P, Mc Fann K, Tkachenko O, Yan XD, Schrier RW.

Am J Nephrol. 2012;36(4):362-70. doi: 10.1159/000343281. Epub 2012 Oct 4.

41.

Emergent early markers of renal progression in autosomal-dominant polycystic kidney disease patients: implications for prevention and treatment.

Helal I, Reed B, Schrier RW.

Am J Nephrol. 2012;36(2):162-7. doi: 10.1159/000341263. Epub 2012 Jul 26. Review.

42.

Assessment of renal function in heart failure.

Schrier RW, Shchekochikhin D.

J Am Coll Cardiol. 2012 May 8;59(19):1716-8. doi: 10.1016/j.jacc.2011.12.041. No abstract available.

43.

Renal failure in cirrhosis: prerenal azotemia, hepatorenal syndrome and acute tubular necrosis.

Schrier RW, Shchekochikhin D, Ginès P.

Nephrol Dial Transplant. 2012 Jul;27(7):2625-8. doi: 10.1093/ndt/gfs067. Epub 2012 Apr 6. No abstract available.

PMID:
22492830
44.

Glomerular hyperfiltration: definitions, mechanisms and clinical implications.

Helal I, Fick-Brosnahan GM, Reed-Gitomer B, Schrier RW.

Nat Rev Nephrol. 2012 Feb 21;8(5):293-300. doi: 10.1038/nrneph.2012.19. Review.

PMID:
22349487
45.

The impact of type II diabetes mellitus in patients with autosomal dominant polycystic kidney disease.

Reed B, Helal I, McFann K, Wang W, Yan XD, Schrier RW.

Nephrol Dial Transplant. 2012 Jul;27(7):2862-5. doi: 10.1093/ndt/gfr744. Epub 2011 Dec 29.

46.

Analysis of baseline parameters in the HALT polycystic kidney disease trials.

Torres VE, Chapman AB, Perrone RD, Bae KT, Abebe KZ, Bost JE, Miskulin DC, Steinman TI, Braun WE, Winklhofer FT, Hogan MC, Oskoui FR, Kelleher C, Masoumi A, Glockner J, Halin NJ, Martin DR, Remer E, Patel N, Pedrosa I, Wetzel LH, Thompson PA, Miller JP, Meyers CM, Schrier RW; HALT PKD Study Group.

Kidney Int. 2012 Mar;81(6):577-85. doi: 10.1038/ki.2011.411. Epub 2011 Dec 28.

47.

Use of diuretics in heart failure and cirrhosis.

Schrier RW.

Semin Nephrol. 2011 Nov;31(6):503-12. doi: 10.1016/j.semnephrol.2011.09.005. Review.

PMID:
22099507
48.

The science behind hyponatremia and its clinical manifestations.

Schrier RW.

Pharmacotherapy. 2011 May;31(5 Suppl):9S-17S. doi: 10.1592/phco.31.5.9S.

PMID:
21923421
49.

Glomerular hyperfiltration and renal progression in children with autosomal dominant polycystic kidney disease.

Helal I, Reed B, McFann K, Yan XD, Fick-Brosnahan GM, Cadnapaphornchai M, Schrier RW.

Clin J Am Soc Nephrol. 2011 Oct;6(10):2439-43. doi: 10.2215/CJN.01010211. Epub 2011 Sep 8.

50.

Cardiac magnetic resonance assessment of left ventricular mass in autosomal dominant polycystic kidney disease.

Perrone RD, Abebe KZ, Schrier RW, Chapman AB, Torres VE, Bost J, Kaya D, Miskulin DC, Steinman TI, Braun W, Winklhofer FT, Hogan MC, Rahbari-Oskoui F, Kelleher C, Masoumi A, Glockner J, Halin NJ, Martin D, Remer E, Patel N, Pedrosa I, Wetzel LH, Thompson PA, Miller JP, Bae KT; HALT PKD Study Group, Meyers CM.

Clin J Am Soc Nephrol. 2011 Oct;6(10):2508-15. doi: 10.2215/CJN.04610511. Epub 2011 Sep 8.

Supplemental Content

Loading ...
Support Center